Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Class A common stock
-
Shares outstanding
-
4,195,190
-
Total 13F shares
-
333,639
-
Share change
-
-270,893
-
Total reported value
-
$1,414,000
-
Put/Call ratio
-
23%
-
Price per share
-
$4.25
-
Number of holders
-
20
-
Value change
-
-$1,408,180
-
Number of buys
-
6
-
Number of sells
-
7
Institutional Holders of Enlivex Therapeutics Ltd. - Class A common stock (ENLV) as of Q3 2022
As of 30 Sep 2022,
Enlivex Therapeutics Ltd. - Class A common stock (ENLV) was held by
20 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
333,639 shares.
The largest 10 holders included
RENAISSANCE TECHNOLOGIES LLC, Compagnie Lombard Odier SCmA, MORGAN STANLEY, CITADEL ADVISORS LLC, UBS Group AG, GOLDMAN SACHS GROUP INC, Susquehanna International Group Ltd., WELLS FARGO & COMPANY/MN, ACT CAPITAL MANAGEMENT, LLC, and EDMOND DE ROTHSCHILD HOLDING S.A..
This page lists
18
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.